Voyager Therapeutics, Inc. (NASDAQ:VYGR) Major Shareholder Ecor1 Capital, Llc Sells 456,000 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGRGet Rating) major shareholder Ecor1 Capital, Llc sold 456,000 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $7.67, for a total transaction of $3,497,520.00. Following the sale, the insider now owns 4,297,907 shares of the company’s stock, valued at $32,964,946.69. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ecor1 Capital, Llc also recently made the following trade(s):

  • On Wednesday, January 11th, Ecor1 Capital, Llc sold 110,000 shares of Voyager Therapeutics stock. The shares were sold at an average price of $8.50, for a total transaction of $935,000.00.

Voyager Therapeutics Trading Up 12.6 %

Shares of NASDAQ VYGR opened at $8.95 on Thursday. The company has a 50 day simple moving average of $5.85 and a two-hundred day simple moving average of $6.09. Voyager Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $10.60. The stock has a market cap of $345.53 million, a price-to-earnings ratio of -19.46 and a beta of 0.93.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Voyager Therapeutics by 1.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 843,711 shares of the company’s stock valued at $4,996,000 after purchasing an additional 15,761 shares during the period. Marshall Wace LLP acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $1,123,000. BlackRock Inc. increased its holdings in Voyager Therapeutics by 4.7% in the 3rd quarter. BlackRock Inc. now owns 590,504 shares of the company’s stock worth $3,496,000 after acquiring an additional 26,289 shares in the last quarter. Armistice Capital LLC increased its holdings in Voyager Therapeutics by 32.4% in the 3rd quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after acquiring an additional 832,000 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in Voyager Therapeutics by 1,746.8% in the 3rd quarter. Royal Bank of Canada now owns 12,004 shares of the company’s stock worth $71,000 after acquiring an additional 11,354 shares in the last quarter. 59.58% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

(Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Further Reading

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.